BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 388963)

  • 1. Effects of PGI2 on platelet aggregation induced by various stimulants.
    Ohtsu A; Hoshina K; Kurozumi S; Hashimoto Y; Noguchi T; Nicolaou KC
    Nihon Ketsueki Gakkai Zasshi; 1979 Aug; 42(4):659-66. PubMed ID: 388963
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of prostacyclin, 6-keto-PGF1 alpha PGF2 alpha and 15[S]15-methyl-PGF2 alpha on platelet aggregation in vitro.
    Marmo E; Somma A; Ottavo R; Vairo G; Spaziante G; DiMezza F; Paone G
    J Med; 1981; 12(2-3):97-108. PubMed ID: 7024451
    [No Abstract]   [Full Text] [Related]  

  • 3. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
    Grodzińska L; Marcinkiewicz E
    Pharmacol Res Commun; 1979 Feb; 11(2):133-46. PubMed ID: 375247
    [No Abstract]   [Full Text] [Related]  

  • 4. A biphasic effect of prostacyclin (PGI2) on platelet aggregation.
    Jørgensen KA; Dyerberg J; Stoffersen E
    Thromb Res; 1980 Sep; 19(6):877-81. PubMed ID: 6258262
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro.
    Maurin N
    Arzneimittelforschung; 1986 Aug; 36(8):1180-3. PubMed ID: 3096342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23,187.
    Kinlough-Rathbone RL; Packham MA; Reimers HJ; Cazenave JP; Mustard JF
    J Lab Clin Med; 1977 Oct; 90(4):707-19. PubMed ID: 333044
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro.
    Saniabadi AR; Lowe GD; Belch JJ; Barbenel JC; Forbes CD
    Haemostasis; 1984; 14(6):487-94. PubMed ID: 6442909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
    Siess W; Roth P; Weber PC
    Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet sensitivity to prostacyclin in pregnancy and uterine cancer.
    Briel RC; Lippert TH
    Eur J Obstet Gynecol Reprod Biol; 1981 Jun; 12(1):19-23. PubMed ID: 7018952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effect of prostaglandins and an aortic proteoglycan on platelet aggregation and plasma clotting.
    Ts'ao C; Eisenstein R
    Prostaglandins Med; 1979 Sep; 3(3):159-66. PubMed ID: 399532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostacyclin (PGI2) and the effect of phosphodiesterase inhibitors on platelet aggregation.
    Jørgensen KA; Dyerberg J; Stoffersen E
    Pharmacol Res Commun; 1979 Jul; 11(7):605-15. PubMed ID: 388470
    [No Abstract]   [Full Text] [Related]  

  • 12. Control of human and animal platelet aggregation by a new prostacyclin analog.
    Maderna P; Colli S; Sirtori C; Tremoli E; Paoletti R
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():363-9. PubMed ID: 2408447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of prostaglandins in the ADP-induced aggregation of rabbit platelets shown by the use of 15-hydroxyprostaglandin dehydrogenase.
    Wallis RB
    Thromb Haemost; 1978 Jun; 39(3):725-32. PubMed ID: 705701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superoxide dismutase cooperates with prostacyclin to inhibit platelet aggregation: a comparative study in washed platelets and platelet rich plasma.
    Salvemini D; de Nucci G; Vane JR
    Thromb Haemost; 1991 Apr; 65(4):421-4. PubMed ID: 1647553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of platelet aggregation by a new agent, Ticlopidine.
    Ashida SI; Abiko Y
    Thromb Haemost; 1979 Feb; 40(3):542-50. PubMed ID: 425067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ethanol on pathways of platelet aggregation in vitro.
    Rand ML; Packham MA; Kinlough-Rathbone RL; Fraser Mustard J
    Thromb Haemost; 1988 Jun; 59(3):383-7. PubMed ID: 3142075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 7-oxabicyclo[2.2.1]heptane prostacyclin agonists.
    Haslanger MF; Sprague PW; Snitman D; Vu T; Harris DN; Greenberg R; Powell J
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():293-7. PubMed ID: 6221540
    [No Abstract]   [Full Text] [Related]  

  • 18. Phenylbutazone inhibition of equine platelet function.
    Meyers KM; Lindner C; Katz J; Grant B
    Am J Vet Res; 1979 Feb; 40(2):265-70. PubMed ID: 464364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.
    Smith JB; Araki H; Lefer AM
    Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Platelet sensitivity to prostacyclin (PGI2) in patients with juvenile-onset diabetes mellitus (author's transl)].
    Klein K; Sinzinger H; Schernthaner G; Silberbauer K; Prager R
    Wien Klin Wochenschr; 1981 Jul; 93(14):460-2. PubMed ID: 7023074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.